The Middle East is rapidly emerging as a key player in the global life sciences and pharmaceutical industry. With ambitious initiatives, strategic partnerships, and substantial investments, the region is poised to make significant contributions to healthcare innovation.
Over the last decade, the UAE’s pharmaceutical industry has seen a significant transformation, with manufacturing facilities growing from four in 2010 to 23 in 2021. This expansion reflects a strong commitment to boosting regional pharmaceutical capacity, providing affordable, high-quality medicines, and fostering innovation. The local market’s value has surged from $1.5 billion in 2011 to an estimated $3.7 billion in 2021, projected to reach $4.7 billion by 2025. The UAE now produces over 2,500 different medications, serving both domestic and global markets. In 2020, pharmaceutical exports reached $251 million to 48 countries, with an expected increase to $297 million by 2025. While imports remain significant at $2.6 billion in 2020, the sector offers substantial investment opportunities for sustainable growth, according to reports from ADQ.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Inventia announces groundbreaking advancement in 3D cell culture technology
Inventia Life Science, an innovator in 3D cell culture technologies, has announced the launch of RASTRUM Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug discovery and disease research with unprecedented scalability, reproducibility, and efficiency.
Aphra names Justin Untersteiner as CEO
The Australian Health Practitioner Regulation Agency (Ahpra) has appointed Justin Untersteiner as Chief Executive Officer (CEO).
WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls
The World Health Organization (WHO) has signed a Memorandum of Understanding (MoU) with Siriraj Hospital, Mahidol University, Thailand, to strengthen collaboration on trauma, injury, and fall prevention across the WHO South-East Asia Region to address the growing health, social, and economic challenges posed by these issues.
Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services
Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre (PF) SA, and its affiliate entities, for JBIRSPL to acquire 80 per cent equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20 per cent retained by PF.
PanopticAI gets US FDA clearance for contactless vital signs monitoring software
PanopticAI, a startup in remote patient monitoring space, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its contactless vital signs monitoring software.
Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma
In a significant step forward for India’s cancer treatment, Immuneel Therapeutics has unveiled Qartemi, country’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a group of blood cancers.
Axel Klarmeyer joins as CEO at Chamlion International
China-based Chamlion, a pioneer in integrated dental 3D printing solutions, has announced the appointment of Axel Klarmeyer as the Chief Executive Officer (CEO) of Chamlion International, overseeing the company's international business operations.
World Bank supports Bosnia and Herzegovina in strengthening healthcare
The World Bank’s Board of Executive Directors has approved a $75 million Second Health Sectors Programmatic Development Policy Loan for Bosnia and Herzegovina (BiH).
GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs
The Global Health Innovative Technology (GHIT) Fund, headquartered in Japan, has announced a total investment of approximately JPY 2 billion ($12.7 million) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.
NIH to lead implementation of National Plan to End Parkinson's Act in US
With support from the US Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH), the National Institutes of Health (NIH) is leading the implementation of the Dr. Emmanuel Bilirakis and Jennifer Wexton National Plan to End Parkinson’s Act, which was signed into law on July 2, 2024.
